China's Lepu Biopharma H1 revenue rises 12.1% on higher drug sales

Lepu Biopharma

16/09/2026 09:42

Overview
China oncology therapeutics developer's H1 2026 revenue grew 12.1% yr/yr
Domestic commercialization revenue more than doubled, led by MEIYOUHENG and PUYOUHENG sales
Licensing revenue declined due to fewer milestone payments from AstraZeneca and ArriVent deals

Outlook
Company plans to accelerate clinical development of late-stage and innovative drug candidates
Lepu Biopharma to focus on expanding market share of approved oncology products in China
Company aims to advance preclinical molecules to IND stage as soon as practicable

Result Drivers
COMMERCIAL SALES SURGE - Co said domestic commercialization revenue more than doubled, driven by MEIYOUHENG and PUYOUHENG sales
LICENSING REVENUE DECLINE - Co attributed lower licensing revenue to fewer milestone payments from AstraZeneca and ArriVent deals
PIPELINE ADVANCEMENT - Co said multiple oncology assets progressed through clinical stages and combination therapies

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 522.4 mln
 

Analyst Coverage
Wall Street's median 12-month price target for Lepu Biopharma Co Ltd is HK$10.38, about 160.5% above its September 15 closing price of HK$3.99

Reuters Recommended Reads
Sept 14 - Definium's LSD-based anxiety, depression drug scores another trial win
Sept 15 - Former head of Chinese food and drug watchdog jailed for bribery
Sept 14 - Trump downplays report China entities helped Iran before attack that killed US troops

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)